Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Dominican Republic: These 5 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Dominican Republic: These 5 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZYKADIA (ceritinib) generic drug versions launch in the Dominican Republic?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Dominican Republic Patent P2011000074

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in the Dominican Republic?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Dominican Republic Patent P2009000195

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the Dominican Republic?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Dominican Republic Patent P2009000253

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in the Dominican Republic?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Dominican Republic Patent P2009000262

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in the Dominican Republic?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Dominican Republic Patent P2009000280

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

Dominican Republic Branded and Generic Drug Market Assessment, Regulation, and Patent Opportunities

Last updated: October 12, 2026

The Dominican Republic is a commercially attractive but operationally fragmented pharmaceutical market. Private retail pharmacies drive branded and generic sales, while the public sector is a major buyer of essential medicines through centralized procurement. Local manufacturing, imported finished products, contract distribution, and pharmacy chains compete across separate channels. The principal opportunities are generic substitution, chronic-disease medicines, hospital products, biosimilars, local packaging, and public tenders. The main constraints are registration delays, import dependence, price sensitivity, procurement concentration, informal distribution, and limited transparency around market data and intellectual-property enforcement.

How large is the Dominican Republic pharmaceutical market?

Publicly available market-size estimates vary because sources use different definitions of pharmaceutical sales, exclude or include hospital procurement, and treat free-zone manufacturing differently. The market is generally characterized by:

Market characteristic Assessment
Commercial structure Private retail is the largest commercial channel; public procurement is concentrated
Supply base Imported finished drugs dominate, supported by local manufacturers and distributors
Demand Chronic diseases, cardiovascular products, diabetes therapies, anti-infectives, pain medicines, gastrointestinal products, and women’s health
Pricing Highly price-sensitive in generics and public tenders; branded products retain premium pricing where physician and patient loyalty is strong
Distribution Pharmacy chains, independent pharmacies, wholesalers, hospitals, clinics, and government programs
Geographic concentration Santo Domingo and Santiago account for a substantial share of commercial activity
Reimbursement Mixed out-of-pocket, private insurance, contributory social-security coverage, and government-funded programs

The Dominican Republic has a population of more than 11 million and is one of the larger pharmaceutical markets in the Caribbean. Demand is supported by urbanization, private health expenditure, expanding insurance coverage, and the growing prevalence of diabetes, hypertension, obesity, cancer, and renal disease. The market remains more fragmented than those of Mexico, Brazil, Colombia, or Chile.

Which companies compete in the Dominican Republic?

Competition includes:

  • Multinational originator companies selling patented and off-patent products.
  • Regional laboratories from Central America, Mexico, Colombia, Argentina, Spain, and India.
  • Dominican manufacturers producing branded generics, generics, over-the-counter products, and selected hospital medicines.
  • Importers and marketing authorization holders that do not manufacture locally.
  • Pharmacy chains and vertically integrated distributors.
  • Public-sector suppliers participating in tenders administered through government purchasing entities.

Dominican manufacturers can compete effectively in products with relatively simple formulations, stable demand, and manageable quality-control requirements. Imported products retain an advantage in complex injectables, oncology, biologics, high-value specialty drugs, and technologies requiring sophisticated manufacturing or cold-chain infrastructure.

What is the regulatory status of medicines in the Dominican Republic?

The Ministry of Public Health, through the General Directorate of Medicines, Food and Health Products, commonly known as DIGEMAPS, is the principal medicines regulator. DIGEMAPS oversees product registration, manufacturing and distribution establishments, importation controls, pharmacovigilance, advertising controls, and sanitary surveillance.

The principal legal framework includes:

  • General Health Law No. 42-01.
  • Regulation for the Registration and Control of Medicines, Decree No. 246-06.
  • Law No. 20-00 on Industrial Property, as amended.
  • DR-CAFTA implementation legislation and related data-exclusivity provisions.
  • Public procurement rules under Law No. 340-06 and implementing regulations.
  • Social-security and public-health rules governing reimbursement and government supply.

A medicine generally requires a sanitary registration before commercial sale. The registration file typically includes administrative information, product composition, manufacturing information, quality documentation, labeling, stability data, packaging details, and evidence of compliance with applicable good manufacturing practices.

How does medicine registration work?

The practical registration process normally involves:

  1. Appointment of a local representative or registration holder.
  2. Preparation and legalization or authentication of foreign documentation where required.
  3. Submission of the technical and administrative dossier to DIGEMAPS.
  4. Review of quality, safety, efficacy, labeling, and manufacturing information.
  5. Payment of regulatory fees.
  6. Issuance of the sanitary registration.
  7. Maintenance through renewals, variations, and post-market obligations.

Registration timelines can be longer than statutory expectations because of dossier deficiencies, agency workload, requests for clarifications, incomplete legalization, manufacturing-site issues, and product-specific review requirements. A local regulatory team with experience in DIGEMAPS procedures can reduce avoidable delays.

What regulatory opportunities exist?

The strongest regulatory opportunities are in products that can demonstrate quality, supply reliability, competitive pricing, and a clear public-health benefit. These include:

  • Generic medicines for diabetes and hypertension.
  • Fixed-dose combinations that improve adherence.
  • Inhaled and respiratory products.
  • Oncology medicines and supportive-care products.
  • Biosimilars and hospital injectables.
  • Pediatric formulations.
  • Products included in public procurement catalogs.
  • Locally packaged products that reduce logistics costs.
  • Medical nutrition and specialized hospital products.

Companies with multiple products can gain efficiency by building a local regulatory platform rather than managing registrations as isolated transactions. A portfolio approach can reduce repeated legal, translation, legalization, and pharmacovigilance costs.

How strong is intellectual-property protection for medicines?

The Dominican Republic recognizes pharmaceutical patents under Law No. 20-00, as amended to implement international and DR-CAFTA commitments. Patent protection generally lasts 20 years from the filing date, subject to statutory rules and the scope of the granted claims.

Patentable subject matter can include:

  • New chemical compounds.
  • Pharmaceutical compositions.
  • Formulations.
  • Manufacturing processes.
  • Crystalline forms and other solid-state forms, where patentability requirements are met.
  • Selected therapeutic applications, subject to local legal standards.
  • Biotechnological inventions, subject to statutory requirements.

Patent examination and enforcement should be assessed separately. A granted patent can provide a legal exclusion right, but practical value depends on claim scope, validity, local enforcement, evidence, and the commercial importance of the Dominican market.

Does the Dominican Republic have an Orange Book or patent linkage system?

The Dominican Republic does not operate a direct equivalent of the U.S. FDA Orange Book for pharmaceutical patents. There is no generally recognized U.S.-style regulatory certification system under which a generic applicant must certify to listed patents through Paragraph I, II, III, or IV categories.

Sanitary registration and patent enforcement are therefore generally separate processes. A patent holder may need to identify and enforce its rights through civil or other available judicial procedures rather than relying on automatic regulatory blocking.

This separation creates an opportunity for generic applicants but also increases freedom-to-operate risk. A company should conduct a local patent search and claim analysis before filing or commercial launch, particularly for products with formulation, process, or use patents.

Does Dominican law provide pharmaceutical data exclusivity?

DR-CAFTA-related provisions provide protection for undisclosed test data submitted to obtain marketing approval for pharmaceutical products. The standard commercial significance is a five-year period for an innovative pharmaceutical product, subject to statutory conditions and the applicable legal interpretation.

Data exclusivity is distinct from patent protection:

Protection Typical term or effect Main commercial function
Patent Up to 20 years from filing, subject to law Prevents unauthorized commercial exploitation of claimed invention
Pharmaceutical data exclusivity Commonly five years under DR-CAFTA-related rules Restricts reliance on protected regulatory test data
Sanitary registration Maintained through renewals and compliance Authorizes lawful marketing
Regulatory exclusivity Product- and rule-specific May affect approval or market access

Data exclusivity can delay certain generic or follow-on applications even when no valid patent blocks the product. It is therefore material for originator launch planning and generic entry analysis.

When do branded drugs lose exclusivity in the Dominican Republic?

There is no single national exclusivity calendar comparable to the U.S. Orange Book. Loss of exclusivity must be assessed product by product using:

  • Dominican patent filings and granted claims.
  • Priority dates and national-phase records.
  • Patent term calculations.
  • Data-exclusivity periods.
  • Supplementary protections, if available and applicable.
  • Formulation, process, and use patents.
  • Regulatory registration status.
  • Procurement and reimbursement conditions.

A basic exclusivity timeline is:

Event Commercial significance
Patent filing or PCT priority Establishes the relevant patent timeline
Dominican national filing or validation Determines local enforceability
Patent grant Confirms enforceable rights, subject to validity and claim scope
Regulatory approval Allows lawful marketing of the product
Data-exclusivity expiry May open a regulatory pathway for reliance on protected data
Patent expiry Removes the exclusion right for claims that have expired
Generic registration and launch Depends on regulatory, patent, supply, and commercial readiness

A generic company should not assume that patent expiry automatically permits immediate launch. Regulatory registration, import approvals, local labeling, inventory planning, pricing, and procurement qualification can create additional timing requirements.

What generic entry risks exist?

Generic entry risk is highest for products with:

  • Multiple active patents.
  • Broad formulation claims.
  • Long-term-release technology.
  • Device or delivery-system components.
  • Complex injectables.
  • Biologics and biosimilars.
  • Narrow therapeutic windows.
  • Manufacturing processes that are difficult to replicate.
  • Strong physician preference or distributor control.

Generic entry risk is lower for older, widely used immediate-release products with multiple registered suppliers and no visible active patent barriers.

Are Paragraph IV challenges available?

The U.S. Paragraph IV mechanism does not directly apply in the Dominican Republic. A generic company generally cannot rely on a U.S.-style certification as a complete local safe harbor. It must evaluate local patents independently and manage infringement risk through freedom-to-operate analysis, non-infringement positions, invalidity arguments, licensing, or launch timing.

A U.S. Paragraph IV challenge may still provide useful commercial intelligence. It can reveal patent weaknesses, litigation positions, settlement terms, and expected launch dates in another jurisdiction, but it does not determine Dominican legal outcomes.

What formulation and method-of-use patents matter?

Formulation patents can remain commercially important after a basic compound patent expires. Relevant claims may cover:

  • Extended-release tablets.
  • Enteric coatings.
  • Particle-size distributions.
  • Polymorphs and crystalline forms.
  • Stabilizers and preservatives.
  • Fixed-dose combinations.
  • Injectable compositions.
  • Device-drug combinations.
  • Storage and reconstitution systems.

Method-of-use patents may cover a specific indication, patient population, dosing schedule, or treatment sequence. Their practical enforceability depends on claim construction, prescribing behavior, labeling, induced-infringement theories, and the available evidence.

Generic applicants should separate product claims from use claims. A product may be commercially viable if it can launch with a lawful label that omits a protected indication, but this strategy requires a detailed regulatory and patent analysis.

How does public procurement affect market access?

Public procurement is one of the most important routes to volume but also one of the most price-competitive. PROMESE/CAL is a central government institution involved in the procurement and distribution of medicines and health products for public facilities and social programs.

Public-sector opportunities depend on:

  • Tender eligibility.
  • Sanitary registration.
  • Good manufacturing practice documentation.
  • Local representation.
  • Product specifications.
  • Bid security and performance guarantees.
  • Delivery capacity.
  • Working capital.
  • Compliance history.
  • Ability to maintain supply over the contract period.

A low bid without reliable inventory can create penalties, reputational damage, and exclusion from future opportunities. Suppliers must price foreign-exchange exposure, freight, customs processing, warehousing, and payment timing.

Private pharmacy sales provide better pricing flexibility but require commercial investment in field promotion, distributor relationships, pharmacy coverage, medical education, and inventory management.

What FDA and international regulatory status affects Dominican launches?

Dominican approval is not an automatic consequence of FDA, European Medicines Agency, or other foreign approval. Foreign approvals can support the technical dossier and may improve regulatory credibility, but DIGEMAPS retains authority over local registration.

Foreign reference approvals can be commercially valuable for:

  • New chemical entities.
  • Complex generics.
  • Biosimilars.
  • Vaccines.
  • Sterile injectables.
  • Products with limited local experience.

Companies should verify whether the Dominican dossier can rely on certificates of pharmaceutical product, reference-country approvals, foreign manufacturing inspections, stability data, and recognized regulatory pathways. Requirements may vary by product category and current DIGEMAPS practice.

What biosimilar risks and opportunities exist?

The Dominican market has potential for biosimilars because biologics are expensive and public and private payers face pressure to contain costs. Key opportunities include oncology biologics, insulin products, erythropoietins, granulocyte colony-stimulating factors, and selected immunology products.

Biosimilar challenges include:

  • More demanding analytical and clinical evidence.
  • Cold-chain requirements.
  • Pharmacovigilance obligations.
  • Physician concerns about interchangeability.
  • Tender specifications favoring an established reference product.
  • Limited local biologics manufacturing capacity.
  • Dependence on foreign manufacturing sites.
  • Higher working-capital needs.

A biosimilar strategy should combine regulatory evidence with hospital-account management, pharmacovigilance capability, supply reliability, and payer engagement. Price alone is unlikely to secure durable uptake.

Which companies are challenging branded products?

Public information does not provide a complete, centralized database of all Dominican generic challengers, Paragraph IV litigants, or product-specific patent disputes. The competitive challenge is typically commercial and regulatory rather than organized through a U.S.-style public patent-certification system.

Generic competition commonly comes from:

  • Dominican laboratories.
  • Regional Latin American manufacturers.
  • Indian and Asian suppliers.
  • Multinational generic companies.
  • Local importers representing foreign manufacturers.

A reliable challenger map requires product-level review of DIGEMAPS registrations, procurement awards, pharmacy availability, distributor records, patent databases, and court filings. Public sources do not support a complete market-wide list of challengers across all therapeutic categories.

What litigation and settlement risks affect pharmaceutical companies?

Pharmaceutical disputes can involve:

  • Patent infringement.
  • Patent validity.
  • Trademark and trade dress.
  • Regulatory data protection.
  • Unfair competition.
  • Parallel imports.
  • Counterfeit products.
  • Procurement disqualification.
  • Distribution and agency agreements.
  • Product liability.
  • Advertising and promotional compliance.

Settlement agreements may include launch licenses, supply arrangements, geographic restrictions, non-compete terms, or agreed launch dates. Their enforceability depends on Dominican contract, competition, patent, and procedural law. A foreign settlement does not automatically bind Dominican operations unless local rights and entities are covered.

What licensing opportunities exist?

Licensing opportunities are strongest where a foreign product owner lacks:

  • Local regulatory infrastructure.
  • Distributor coverage.
  • Public-tender capability.
  • Spanish-language labeling and pharmacovigilance support.
  • Cold-chain capacity.
  • Local manufacturing or packaging.
  • Relationships with private insurers and hospital groups.

Potential structures include:

Structure Best use
Exclusive distribution Established imported product with limited local operating requirements
Marketing authorization transfer Local company assumes regulatory ownership and commercial control
Co-promotion Originator retains technical control while adding local commercial reach
Local packaging or manufacturing license Reduces logistics costs and supports public tenders
Technology transfer Builds Dominican production for selected generics or hospital products
Regional license Covers the Dominican Republic and nearby Caribbean markets

Deal diligence should address registration ownership, supply continuity, minimum purchase obligations, pharmacovigilance, recalls, quality audits, price controls, tender participation, currency risk, and termination rights.

What are the main regulatory and commercial challenges?

The principal challenges are:

  1. Registration and variation timelines can be difficult to predict.
  2. Imported products face customs, freight, currency, and inventory risks.
  3. Public tenders create significant price compression.
  4. Private retail channels are relationship-driven and fragmented.
  5. Enforcement against counterfeit and unauthorized products can be uneven.
  6. Patent information is not consolidated in an Orange Book-style source.
  7. Local data on product sales, inventory, and market share is limited.
  8. Complex products require higher evidence, quality, and pharmacovigilance capabilities.
  9. Payment cycles can affect smaller suppliers.
  10. Regulatory changes require continuous local monitoring.

What is the market-entry strategy for branded and generic drugs?

A practical entry strategy should use separate plans for private retail, hospitals, and public procurement.

For branded products, the priorities are local registration ownership, physician and pharmacy access, distributor economics, reimbursement positioning, and protection of trademarks and patents.

For generics, the priorities are freedom-to-operate analysis, bioequivalence or comparative evidence, competitive cost of goods, reliable supply, multiple channel registrations, and tender readiness.

For complex products, the strategy should begin with technical and regulatory feasibility before commercial launch commitments. Biosimilars, sterile injectables, inhaled products, and modified-release formulations require earlier quality, pharmacovigilance, and manufacturing planning than standard oral generics.

Key Takeaways

  • The Dominican Republic is a growing but fragmented pharmaceutical market with strong private-retail and public-procurement channels.
  • DIGEMAPS is the central regulator for medicine registration, manufacturing, importation, and post-market control.
  • Patent protection generally extends up to 20 years from filing, while pharmaceutical regulatory data protection is commonly five years under DR-CAFTA-related rules.
  • The country does not operate a direct U.S.-style Orange Book or Paragraph IV system.
  • Generic entry requires local patent, data-exclusivity, regulatory, and commercial analysis.
  • Formulation, process, use, device, and biologic patents can remain important after basic compound protection ends.
  • Public tenders offer volume but impose severe pricing and supply requirements.
  • The strongest opportunities are chronic-care generics, hospital products, biosimilars, pediatric medicines, local packaging, and contract manufacturing.
  • The most effective market entrants combine a local regulatory representative, reliable distributor coverage, tender capability, and product-specific intellectual-property diligence.

FAQs

Is a Dominican Republic sanitary registration required for imported generic drugs?

Yes. Imported generic medicines generally require a Dominican sanitary registration before commercial distribution, supported by technical, manufacturing, labeling, and quality documentation.

Can a generic launch in the Dominican Republic before a U.S. patent expires?

Possibly, but U.S. patent expiry does not determine Dominican freedom to operate. The applicant must analyze Dominican patents, data exclusivity, regulatory requirements, and local enforcement risk.

Are biosimilars automatically interchangeable in the Dominican Republic?

No automatic assumption should be made. Regulatory approval, interchangeability, substitution, procurement specifications, and clinical practice must be assessed under the applicable Dominican framework and product-specific requirements.

Does the Dominican Republic recognize FDA approval as local approval?

No. FDA approval can support a Dominican application but does not replace DIGEMAPS registration or local compliance requirements.

What is the fastest commercial route for an off-patent medicine?

The fastest route is generally a complete registration dossier supported by a compliant foreign manufacturer, an experienced local representative, accurate Spanish labeling, and a distribution plan that covers both private pharmacies and public procurement.

References

  1. Dominican Republic. (2001). General Health Law No. 42-01.

  2. Dominican Republic. (2006). Decree No. 246-06: Regulation for the Registration and Control of Medicines.

  3. Dominican Republic. (2000, as amended). Law No. 20-00 on Industrial Property.

  4. Dominican Republic. (2006, as amended). Law No. 340-06 on Public Procurement of Goods, Works, Services and Concessions.

  5. Dirección General de Medicamentos, Alimentos y Productos Sanitarios. (n.d.). Regulatory procedures and requirements for medicines. Ministry of Public Health of the Dominican Republic.

  6. Office of the United States Trade Representative. (2007). Dominican Republic-Central America-United States Free Trade Agreement: Intellectual property provisions.

  7. World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights.

  8. World Health Organization. (2023). Global monitoring framework for noncommunicable diseases and country health-system information. WHO.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.